Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

K. pneumoniae infection

Supported pathogenK. pneumoniaeKlebsiella pneumoniae

Medicines already documented

Documented evidence

Registered studies whose listed conditions mention “klebsiella”, “k. pneumoniae”, “k pneumoniae”, “k. pneumoniae infection”.

Laboratory measurements against K. pneumoniae recorded in ChEMBL.

Show all 82

Other medicines to investigate

AI prediction · nothing measured

Approved medicines with AI-predicted activity ≥40% against K. pneumoniae that are not already antimicrobials, have no registered study for this condition and have no laboratory record against it. Each shows what it is already used for. They were surfaced computationally for further investigation and are not presented as established treatments for this condition.

K. pneumoniae has 85 repurposing candidates in all. 3 are already listed above, with a registered study for this condition or a laboratory record, so the other 82 are listed here.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Every repurposing candidate for K. pneumoniae, including those with documented evidence →

Registered studies

A registration describes a study; it does not establish a positive result.

When these studies started7 of 7 have a start date · most in 2019 (2)
200520142023

  • Dose Optimization by Pharmacokinetic/Pharmacodynamic of Antibiotics to Improve Clinical Outcome of Carbapenem Resistant Klebsiella Pneumoniae Bloodstream Infections in Critically Ill Patients at Phramongkutklao Hospital

    NCT05862402 · start 2023-05-07

    Registered record
    Registry ID
    NCT05862402
    Conditions
    Carbapenem Resistant Klebsiella Pneumoniae
    Interventions
    Dose-adjustment by PKPD
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2023-05-07
    Completion
    2024-06-30
    Enrolment
    76

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarbapenem Resistant Klebsiella Pneumoniae
    InterventionDose-adjustment by PKPD
    PhasePhase 4
    Registry statusUnknown

  • Comparative Clinical Study Between Colistin-Tigecycline Combined Therapy Versus Colistin-Meropenem Combined Therapy in Treatment of Blood Stream Infections With Multidrug-Resistant Klebsiella Pneumoniae

    NCT04489459 · start 2019-09-21

    Registered record
    Registry ID
    NCT04489459
    Conditions
    Treatment of Blood Stream Infections Due to Multidrug-Resistant Klebsiella Pneumoniae
    Interventions
    Colistin; Meropenem; Tigecycline
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2019-09-21
    Completion
    2020-07
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTreatment of Blood Stream Infections Due to Multidrug-Resistant Klebsiella Pneumoniae
    InterventionColistin; Meropenem; Tigecycline
    PhasePhase 4
    Registry statusUnknown

  • Piperacillin/Tazobactam Versus Carbapenems in Non-bacteremic UTI Due to -ESBL-producing Enterobacteriaceae

    NCT03891433 · start 2019-04-01

    Registered record
    Registry ID
    NCT03891433
    Conditions
    Urinary Tract Infections; Enterobacteriaceae Infections; Infection Due to ESBL Bacteria; Carbapenem; Escherichia Coli Infection; Klebsiella Pneumoniae Infection; Clinical Trial; Drug Resistance, Bacterial
    Interventions
    Meropenem; Ertapenem 1000 MG; Piperacillin, Tazobactam 4-0.5G Solution for Injection
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Suspended
    Start
    2019-04-01
    Completion
    2026-04-01
    Enrolment
    198

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUrinary Tract Infections; Enterobacteriaceae Infections; Infection Due to ESBL Bacteria; Carbapenem +4 more
    InterventionMeropenem; Ertapenem 1000 MG; Piperacillin, Tazobactam 4-0.5G Solution for Injection
    PhasePhase 4
    Registry statusSuspended

  • Sitafloxacin and Ertapenem Treatment for Acute Urinary Tract Infection Caused by E. Coli or K. Pneumoniae in Post-kidney Transplantation Patients

    NCT02729116 · start 2016-07

    Registered record
    Registry ID
    NCT02729116
    Conditions
    Anti-Infective Agents, Urinary; Escherichia Coli Infections; Klebsiella Infections; Kidney Transplantation; Urinary Tract Infections
    Interventions
    Sitafloxacin; Ertapenem
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Unknown
    Start
    2016-07
    Completion
    2024-01
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnti-Infective Agents, Urinary; Escherichia Coli Infections; Klebsiella Infections; Kidney Transplantation +1 more
    InterventionSitafloxacin; Ertapenem
    PhasePhase 2 / Phase 3
    Registry statusUnknown

  • Efficacy of Intestinal Decontamination in Patients Colonized by Carbapenem-resistant Klebsiella Pneumoniae and Colistin

    NCT02604849 · start 2012-07

    Registered record
    Registry ID
    NCT02604849
    Conditions
    Patients Colonized by Klebsiella Pneumoniae.
    Interventions
    Neomycin; Streptomycin; Gentamicins
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2012-07
    Completion
    2015-11
    Enrolment
    44

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPatients Colonized by Klebsiella Pneumoniae.
    InterventionNeomycin; Streptomycin; Gentamicins
    PhaseNot recorded
    Registry statusCompleted

  • A Study Evaluating the Role of Oral Antibiotics in an Aim to Eradicate Carrier State of Carbapenem- Resistant Klebsiella Pneumonia (KPC).

    NCT01266499 · start 2009-07

    Registered record
    Registry ID
    NCT01266499
    Conditions
    Klebsiella Pneumoniae Carbapenemase Resistant Associated Bacteremia or Pneumonia
    Interventions
    Colistin (Polymyxin E) 100mg x 4/d; both medications; will not receive PO treatment; PO Garamycin 80mg x 4/d
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2009-07
    Completion
    2012-01
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionKlebsiella Pneumoniae Carbapenemase Resistant Associated Bacteremia or Pneumonia
    InterventionColistin (Polymyxin E) 100mg x 4/d; both medications; will not receive PO treatment; PO Garamycin 80mg x 4/d
    PhaseNot applicable
    Registry statusCompleted

  • Study Evaluating Piperacillin-Tazobactam on Certain Bacteria in Hematology and Oncology Units

    NCT00167999 · start 2005-02

    Registered record
    Registry ID
    NCT00167999
    Conditions
    Gram-Positive Bacterial Infections; Escherichia Coli Infections; Klebsiella Infections
    Interventions
    piperacillin-tazobactam
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2005-02
    Completion
    Not recorded
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGram-Positive Bacterial Infections; Escherichia Coli Infections; Klebsiella Infections
    Interventionpiperacillin-tazobactam
    PhaseNot recorded
    Registry statusCompleted